Want to see RAPP full AI Analyst Report?

Rapport Therapeutics, Inc. (RAPP) Price & Analysis

149 Followers

RAPP Stock Chart & Stats

$40.68

$1.42(3.49%)

At close: Jul 27 4:00 PM EDT

$40.68

$1.42(3.49%)

Day’s Range― - ―

52-Week Range$13.86 - $49.50

Previous CloseN/A

Volume230.44K

Average Volume (3M)404.29K

Market Cap

$2.32B

Enterprise Value$1.55K

Total Cash (Recent Filing)$436.08M

Total Debt (Recent Filing)$10.11M

Price to Earnings (P/E)―

Beta1.65

Next Earnings

Nov 05, 2026

EPS Estimate

-1.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.04

Shares Outstanding47,978,287

10 Day Avg. Volume321,428

30 Day Avg. Volume404,290

Financial Highlights & Ratios

PEG Ratio0.44

Price to Book (P/B)2.94

Price to Sales (P/S)0.00

P/FCF Ratio-16.18

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$60.25

Price Target Upside48.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-4.01

Revenue Forecast (FY)$20.00M

Bulls Say, Bears Say

Bulls Say

Pipeline AdvancementProgress into Phase 3 and enrollment across seizure studies increase the pipeline’s potential commercial value. Additional bipolar mania, injectable, and generalized seizure programs provide indication diversification and multiple future development milestones.

High Gross MarginEarly revenue paired with very high gross margin suggests an attractive underlying product economics profile if commercialization expands. This provides operating leverage potential, although substantial development spending currently outweighs gross profitability.

Low Financial LeverageMinimal debt reduces interest burden and solvency pressure while the company funds clinical development. Its $459.0M asset base provides financial capacity, giving management greater flexibility than a highly leveraged development-stage biotech.

Bears Say

Deep Operating LossesThe company remains far from profitability despite emerging revenue, as heavy R&D and operating expenses drive losses. Sustained negative earnings limit internal funding capacity and make successful clinical and commercial execution essential to long-term value creation.

Substantial Cash BurnLarge recurring cash outflows mean clinical advancement consumes significant capital before products generate meaningful cash returns. Even if burn is stabilizing, continued investment could require additional financing and increase dilution risk over the development cycle.

Nascent Revenue BaseRecent revenue traction is encouraging but remains too limited to establish durable earnings visibility. The company’s historical lack of revenue and negative returns leave performance highly dependent on clinical outcomes, regulatory progress, and eventual product adoption.

Rapport Therapeutics, Inc. News

Rapport Therapeutics price target raised to $75 from $68 at Raymond James

Raymond James analyst Tiago Fauth raised the firm’s price target on Rapport Therapeutics (RAPP) to $75 from $68...

2d ago

RAPP

Rapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rapport Therapeutics (RAPP) to $66 from $40...

2d ago

RAPP

Rapport Therapeutics reports Q2 EPS ($1.19), consensus (99c)

“We remain focused on disciplined execution as we deliver against several important catalysts this year,” said Abraham N....

14d ago

RAPP

Rapport Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $79.03 fair value estimate. Rapport...

22d ago

RAPP

Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 Data

H.C. Wainwright analyst Douglas Tsao has maintained their bullish stance on RAPP stock, giving a Buy rating on...

7d ago

RAPP

Rapport Therapeutics: Advancing Phase 3 Epilepsy Pipeline and De-Risked Development Path Underpins Buy Rating

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Rapport Therapeutics, Inc.,...

13d ago

RAPP

Myles Minter Initiates Buy on Rapport Therapeutics, Citing De-Risked RAP-219 Epilepsy Program and Multi-Billion-Dollar Peak Sales Potential

William Blair analyst Myles Minter has maintained their bullish stance on RAPP stock, giving a Buy rating on...

14d ago

RAPP

RAP-219’s Differentiated Mechanism Supports Unchanged $65 Price Target and Reiterated Buy on Rapport Therapeutics

BTIG analyst Kambiz Yazdi maintained a Buy rating on Rapport Therapeutics, Inc. yesterday and set a price target...

1M ago

RAPP

Rapport Therapeutics management to meet with Citizens

Meeting to be held in Boston on July 21 hosted by Citizens. Published first on TheFly – the...

1M ago

RAPP

Rapport Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $52 price target The epilepsy market...

2M ago

RAPP

Rapport Therapeutics management to meet with Citizens

Meeting to be held in Boston on June 23 hosted by Citizens. Published first on TheFly – the...

2M ago

RAPP

Rapport Therapeutics Holds 2026 Annual Shareholder Meeting

Rapport Therapeutics, Inc. ( ($RAPP) ) just unveiled an announcement. On June 10, 2026, Rapport Therapeutics, Inc. held...

2M ago

RAPP

RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

Rapport Therapeutics, Inc. ($RAPP) announced an update on their ongoing clinical study. The phase 3 study “A Phase...

3M ago

RAPP

Rapport Therapeutics price target raised to $65 from $53 at BTIG

BTIG raised the firm’s price target on Rapport Therapeutics (RAPP) to $65 from $53 and keeps a Buy...

3M ago

RAPP

RAPP FAQ

What was Rapport Therapeutics, Inc.’s price range in the past 12 months?

Rapport Therapeutics, Inc. lowest stock price was $13.86 and its highest was $49.50 in the past 12 months.

What is Rapport Therapeutics, Inc.’s market cap?

Rapport Therapeutics, Inc.’s market cap is $2.32B.

When is Rapport Therapeutics, Inc.’s upcoming earnings report date?

Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.

How were Rapport Therapeutics, Inc.’s earnings last quarter?

Rapport Therapeutics, Inc. released its earnings results on Aug 05, 2026. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$0.07.

Is Rapport Therapeutics, Inc. overvalued?

According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rapport Therapeutics, Inc. pay dividends?

Rapport Therapeutics, Inc. does not currently pay dividends.

What is Rapport Therapeutics, Inc.’s EPS estimate?

Rapport Therapeutics, Inc.’s EPS estimate is -1.21.

How many shares outstanding does Rapport Therapeutics, Inc. have?

Rapport Therapeutics, Inc. has 47,978,287 shares outstanding.

What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?

Rapport Therapeutics, Inc. reported an EPS of -$1.19 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went up 0.569%.

Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?

Currently, no hedge funds are holding shares in RAPP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rapport Therapeutics, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

60.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

Rapport Therapeutics, Inc. (RAPP) Earnings & Revenues

Historic Earnings Reports

RAPP Stock 12 Month Forecast

Average Price Target

$60.25

▲(48.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","76":"$76","28.75":"$28.8","44.5":"$44.5","60.25":"$60.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,28.75,44.5,60.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.98,43.596923076923076,46.21384615384615,48.83076923076923,51.44769230769231,54.06461538461538,56.68153846153846,59.29846153846154,61.91538461538461,64.53230769230768,67.14923076923077,69.76615384615384,72.38307692307691,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.98,42.46230769230769,43.94461538461538,45.426923076923075,46.90923076923077,48.39153846153846,49.87384615384615,51.356153846153845,52.83846153846154,54.32076923076923,55.80307692307692,57.285384615384615,58.76769230769231,{"y":60.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.98,41.67384615384615,42.3676923076923,43.06153846153846,43.755384615384614,44.449230769230766,45.14307692307692,45.83692307692308,46.53076923076923,47.22461538461538,47.918461538461536,48.612307692307695,49.30615384615385,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.37,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.89,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.11,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.98,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >